Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)
Meeting – March 13, 2024 @ 4:00pm
at the
Oklahoma Health Care Authority (OHCA)
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

NOTE: ***The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.***

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call to Order**

A. Roll Call – Dr. Wilcox

DUR Board Members:

Mr. Kenneth Foster –	participating in person
Dr. Megan Hanner –	participating in person
Dr. Bret Haymore –	participating in person
Dr. John Muchmore –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person
Dr. Edna Patatanian –	participating in person
Dr. Vineetha Thomas –	participating in person
Dr. Beth Walton –	participating in person
Dr. Cindy West –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:
https://oklahoma.zoom.us/webinar/register/WN_R_AmCBepQpGQggKXT40uxg
After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:
Dial: +1-602-753-0140 or +1-669-219-2599
Webinar ID: 919 6475 4191
Passcode: 95646190

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the Speaker Registration Form. Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
   A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**
   A. February 14, 2024 DUR Board Meeting Minutes
   B. February 14, 2024 DUR Board Recommendations Memorandum
   C. Correspondence

Items to be presented by Dr. O'Halloran, Dr. Morgan, Dr. Muchmore, Chairman:

4. **Update on Medication Coverage Authorization Unit/Spring 2024 Pipeline Update – See Appendix B**
   A. Pharmacy Help Desk Activity for February 2024
   B. Medication Coverage Activity for February 2024
   C. Spring 2024 Pipeline Update

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

5. **Action Item – Vote to Prior Authorize RizaFilm® (Rizatriptan Film) and Zavzpret™ (Zavegepant Nasal Spray) and Update the Approval Criteria for the Anti-Migraine Medications – See Appendix C**
   A. Market News and Updates
   B. Product Summaries
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

6. **Action Item – Vote to Prior Authorize Alinia® (Nitazoxanide Tablet) and Xdemvy™ (Lotilaner Ophthalmic Solution) and Update the Approval Criteria for the Anti-Parasitic Medications – See Appendix D**
   A. Market News and Updates
   B. Product Summaries
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Morgan, Dr. Muchmore, Chairman:

7. **Action Item – Vote to Prior Authorize Ycanth™ (Cantharidin) and Zelsuvmi™ (Berdazimer) – See Appendix E**
   A. Market News and Updates
   B. Product Summaries
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Sinko, Dr. Muchmore, Chairman:

8. **Action Item – Vote to Prior Authorize Vanflyta® (Quizartinib) and Update the Approval Criteria for the Leukemia Medications – See Appendix F**
   A. Market News and Updates
   B. Vanflyta® (Quizartinib) Product Summary
   C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

9. **Action Item – Annual Review of Skyclarys™ (Omaveloxolone) – See Appendix G**
   A. Current Prior Authorization Criteria
   B. Utilization of Skyclarys™ (Omaveloxolone)
   C. Prior Authorization of Skyclarys™ (Omaveloxolone)
   D. Market News and Updates
   E. College of Pharmacy Recommendations
   F. Utilization Details of Skyclarys™ (Omaveloxolone)

Items to be presented by Dr. Morgan, Dr. Muchmore, Chairman:

10. **Action Item – Annual Review of Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Medications – See Appendix H**
    A. Current Prior Authorization Criteria
    B. Utilization of VMAT2 Inhibitor Medications
    C. Prior Authorization of VMAT2 Inhibitor Medications
    D. Market News and Updates
    E. College of Pharmacy Recommendations
    F. Utilization Details of VMAT2 Inhibitor Medications

Items to be presented by Dr. Sinko, Dr. Muchmore, Chairman:

11. **Annual Review of Lymphoma Medications and 30-Day Notice to Prior Authorize Columvi™ (Glofitamab-gxbm) and Epkinly™ (Epcoritamab-bysp) – See Appendix I**

A. Current Prior Authorization Criteria
B. Utilization of Lymphoma Medications
C. Prior Authorization of Lymphoma Medications
D. Market News and Updates
E. Product Summaries
F. College of Pharmacy Recommendations
G. Utilization Details of Lymphoma Medications

Items to be presented by Dr. Ratterman, Dr. Muchmore, Chairman:

12. **Annual Review of Hemophilia Medications and 30-Day Notice to Prior Authorize Roctavian™ (Valoctocogene Roxaparvovec-rvox) – See Appendix J**

A. Current Prior Authorization Criteria
B. Utilization of Hemophilia Medications
C. Prior Authorization of Hemophilia Medications
D. Market News and Updates
E. Roctavian™ (Valoctocogene Roxaparvovec-rvox) Product Summary
F. Oklahoma Health Care Authority (OHCA) Recommendations
G. Utilization Details of Hemophilia Medications

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

13. **Annual Review of Growth Hormone Products and Voxzogo® (Vosoritide) and 30-Day Notice to Prior Authorize Ngenla™ (Somatrogon-ghla) – See Appendix K**

A. Current Prior Authorization Criteria
B. Utilization of Growth Hormone Products and Voxzogo® (Vosoritide)
C. Prior Authorization of Growth Hormone Products and Voxzogo® (Vosoritide)
D. Market News and Updates
E. Ngenla® (Somatrogon-ghla) Product Summary
F. College of Pharmacy Recommendations
G. Utilization Details of Growth Hormone Products and Voxzogo® (Vosoritide)

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

14. **Annual Review of Granulocyte Colony-Stimulating Factors (G-CSFs) and 30-Day Notice to Prior Authorize Ryzneuta® (Efbemalenograstim Alfa) – See Appendix L**

A. Current Prior Authorization Criteria
B. Utilization of G-CSFs
C. Prior Authorization of G-CSFs
D. Market News and Updates
E. Ryzneuta® (Efbemalenograstim Alfa) Product Summary

F. College of Pharmacy Recommendations
G. Utilization Details of G-CSFs

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

15. Annual Review of Multiple Sclerosis (MS) Medications and 30-Day Notice to Prior Authorize Tyruko® (Natalizumab-sztn) – See Appendix M

A. Current Prior Authorization Criteria
B. Utilization of MS Medications
C. Prior Authorization of MS Medications
D. Market News and Updates
E. College of Pharmacy Recommendations
F. Utilization Details of MS Medications

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

16. Annual Review of Stem Cell Mobilizers and 30-Day Notice to Prior Authorize Aphexda™ (Motixafortide) – See Appendix N

A. Current Prior Authorization Criteria
B. Utilization of Stem Cell Mobilizers
C. Prior Authorization of Stem Cell Mobilizers
D. Market News and Updates
E. Aphexda™ (Motixafortide) Product Summary
F. College of Pharmacy Recommendations
G. Utilization Details of Stem Cell Mobilizers

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

17. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix O

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

18. Future Business* (Upcoming Product and Class Reviews)

A. Age-Related Macular Degeneration (AMD) Medications
B. Anti-Diabetic Medications
C. Attention-Deficit/Hyperactivity Disorder (ADHD) and Narcolepsy Medications
D. Phenylketonuria Medications

*Future product and class reviews subject to change.

19. Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.